Skip To Main Content
Barbora Weinbergerova on Muck Rack

Barbora Weinbergerova

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbora

Contact Barbora, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients - Leukemia

|
By Marius Bill, Jan-Niklas Eckardt, Christian Rausch, Klaus H. Metzeler, Karsten Spiekermann, Sebastian Stasik, Alexander A. Wurm, Ulf Schnetzke, Andreas Hochhaus Verified, Bernhard Wörmann, Hermann Einsele, Dennis Görlich, Andreas Burchert, Christoph Schliemann, Stefan Krause, Maher Hanoun, Johannes Schetelig, Jan Moritz Middeke, Lars Bullinger, Michael Heuser, Felicitas Thol, Claudia D. Baldus, Carsten Müller-Tidow, Jan Valka, Barbora Weinbergerova, Pierre-Yves Dumas, Sarah Bertoli, Eric Delabesse, Christian Récher, Arnaud Pigneux, Tobias Herold, Maximillian-Alexander Röhnert
| Nature Verified
Abstract In the European LeukemiaNet (ELN) 2022 recommendations, myelodysplasia-related (MR) gene mutations were classified as a novel adverse prognostic category for intensively treated acute myeloid leukemia (AML). To assess the prognostic impact of individual MR genes within the ELN, clinical, cytogenetic, and molecular data from 4,978 intensively treated AML patients were analyzed. Remission rates and survival outcomes were evaluated.
Open in Who Shared Issue with article?

Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation - Leukemia

|
By Lubos Janotka, Alena Pecinová, David Kundrát, Dusan Hrckulak, Barbora Weinbergerova, Sarka Pospisilova, Michael Doubek, Vladimir Divoky, Jakub Onhajzer
| Nature Verified
Abstract The acquired JAK2-V617F mutation plays a causal role in myeloproliferative neoplasms (MPN). Weakly activating JAK2 germline variants have been associated with MPN risk, but the underlying mechanisms remain unclear. We previously identified the JAK2-R1063H germline variant, which contributes to hereditary MPN and increased disease severity in essential thrombocythemia. Here, we studied alterations in hematopoiesis in Jak2-R1063H knock-in mice.
Open in Who Shared Issue with article?

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis - Leukemia

|
By Philippe Müller, Sven Zukunft, Barbora Weinbergerova, Jan Valka, Carolin Krekeler, Lutz Muller, Patrick Hess, Madlen Jentzsch, Franziska Modemann, Björn Steffen, Stefan Krause, Karsten Spiekermann, Claudia D. Baldus, Carsten Müller-Tidow, Georg Lenz, Christoph Röllig, Christoph Schliemann
| Nature Verified
Abstract The addition of gemtuzumab ozogamicin (GO) to intensive chemotherapy (IC) has become a mainstay in treating patients with core binding factor acute myeloid leukemia (CBF-AML). However, evidence for the efficacy of GO in this particular subgroup is primarily based on meta-analytic data from different trials conducted more than a decade ago.
Open in Who Shared Issue with article?
See all 5 articles